Results 201 to 210 of about 8,708 (251)
Some of the next articles are maybe not open access.
Journal of Antimicrobial Chemotherapy
OBJECTIVES Ceftolozane/tazobactam has been developed as a novel carbapenem-sparing agent. Our study aimed at comparing the effectiveness of ceftolozane/tazobactam versus meropenem for the treatment of bloodstream infections (BSIs) due to ESBL producers.
Dimtrios Basoulis +10 more
semanticscholar +1 more source
OBJECTIVES Ceftolozane/tazobactam has been developed as a novel carbapenem-sparing agent. Our study aimed at comparing the effectiveness of ceftolozane/tazobactam versus meropenem for the treatment of bloodstream infections (BSIs) due to ESBL producers.
Dimtrios Basoulis +10 more
semanticscholar +1 more source
The Pediatric Infectious Disease Journal
BACKGROUND Infections caused by drug-resistant Gram-negative bacteria, including carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa, are emerging in pediatric hospitals.
Pauline Labé +8 more
semanticscholar +1 more source
BACKGROUND Infections caused by drug-resistant Gram-negative bacteria, including carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa, are emerging in pediatric hospitals.
Pauline Labé +8 more
semanticscholar +1 more source
International Journal of Antimicrobial Agents
The emerging resistance to cephalosporins and carbapenems in gram-negative pathogens poses significant health challenges and increased treatment failures. The development and evaluation of novel therapeutic options are needed urgently.
Zhong-qiao Yang +5 more
semanticscholar +1 more source
The emerging resistance to cephalosporins and carbapenems in gram-negative pathogens poses significant health challenges and increased treatment failures. The development and evaluation of novel therapeutic options are needed urgently.
Zhong-qiao Yang +5 more
semanticscholar +1 more source
Ceftolozane–tazobactam: A new-generation cephalosporin
American Journal of Health-System Pharmacy, 2015The chemistry, pharmacokinetic and pharmacodynamic properties, efficacy, and safety of the recently introduced combination antimicrobial agent ceftolozane-tazobactam are reviewed.Ceftolozane-tazobactam (Zerbaxa, Cubist Pharmaceuticals) is a cephalosporin β-lactam and β-lactamase inhibitor marketed as a fixed-dose combination agent for the treatment of ...
Cluck, David +4 more
openaire +3 more sources
Therapeutic Drug Monitoring
Supplemental Digital Content is Available in the Text. Background: Ceftolozane/tazobactam (C-T) is a novel beta-lactam/beta-lactamase inhibitor combination approved for the treatment of various infections caused by difficult-to-treat Pseudomonas ...
Matteo Conti +4 more
semanticscholar +1 more source
Supplemental Digital Content is Available in the Text. Background: Ceftolozane/tazobactam (C-T) is a novel beta-lactam/beta-lactamase inhibitor combination approved for the treatment of various infections caused by difficult-to-treat Pseudomonas ...
Matteo Conti +4 more
semanticscholar +1 more source
Infectious Diseases
Purpose This study aimed to present real-life data on the use, effectiveness, and safety of administering Ceftolozane/Tazobactam (C/T) through elastomeric pumps (EP) in the outpatient setting.
G. Giuliano +5 more
semanticscholar +1 more source
Purpose This study aimed to present real-life data on the use, effectiveness, and safety of administering Ceftolozane/Tazobactam (C/T) through elastomeric pumps (EP) in the outpatient setting.
G. Giuliano +5 more
semanticscholar +1 more source
Emerging Microbes and Infections
Although an increased effectiveness has been suggested when phages and antibiotics are combined, this approach has not been tested against a mature biofilm on an endotracheal tube (ETT) surface.
V. Oliveira +6 more
semanticscholar +1 more source
Although an increased effectiveness has been suggested when phages and antibiotics are combined, this approach has not been tested against a mature biofilm on an endotracheal tube (ETT) surface.
V. Oliveira +6 more
semanticscholar +1 more source